STAMFORD, Conn., April 29, 2014 /PRNewswire/ -- Purdue Pharma L.P. will present results from a number of research studies at the American Pain Society (APS) 33rd Annual Scientific Meeting, April 30-May 3, 2014, in Tampa, Fla.
Following is a schedule of select poster presentations:
Title | Authors | Date / Time |
A Single-Center, Randomized, Double-Blind Crossover Study to Evaluate the Abuse Potential, Pharmacokinetics, and Safety of Milled and Intranasally Administered Extended- Release Hydrocodone in Recreational Opioid Users | Harris S, Colucci S, Perrino P, KapilR, Geoffroy P, HopyanT, Levy-Cooperman N | Thursday, May 1 9:30 AM11:00 AM |
A Single-Center, Randomized, Double-Blind, Crossover Study to Evaluate the Abuse Potential, Pharmacokinetics, and Safety of Oral Milled and Intact Extended-Release Hydrocodone (HYD) Tablets in Recreational Opioid Users | Harris S, Colucci S, Perrino P, KapilR, Geoffroy P, HopyanT, Levy-Cooperman N | Friday, May 2 8:45 AM-10:15 AM
|
Long-term Safety and Effectiveness of Once- daily, Single-entity, Abuse-deterrent Hydrocodone in Chronic Nonmalignant and Nonneuropathic Pain: Results of a Long-term Open-label Study | WenW, TaberL, LynchSY, MuneraC, Ripa SR | Thursday, May 1 9:30 AM11:00 AM |
In Vitro Assessment of the Effects of Alcohol on the Release Rate of Hydrocodone Bitartrate from a Once-daily, Single-Entity, Hydrocodone Bitartrate Formulation | Giordano J, Huang H, Kianto J | Friday, May 2 8:45 AM-10:15 AM
|
Comparison of the Risk of Opioid Overdose among Patients Prescribed Immediate-Release and Extended-Release Opioid Analgesics | Coplan P, DeVeaugh-Geiss A, Kadakia A | Thursday, May 1 9:30 AM11:00 AM |
Abuse-deterrent Opioid Analgesic Formulations: Technology, Evaluation, and Labeling | Haddox D | Friday, May 2, 2014 8:45 AM - 10:15 AM
|
Impact of an opioid reformulation with abuse- deterrent properties on doctor-shopping | Chilcoat H, Coplan PM, Sessler NE, Schultz Y, Yuan Y | Friday, May 2, 2014 8:45 AM - 10:15 AM |
Epidemiology of Conditions Associated with Pain and the Use of Analgesic and Non- Analgesic Treatments in Pediatrics | Wallace L, Baldridge S, Matsuno R | Thursday, May 1 9:30 AM 11:00 AM |
Neonatal Abstinence Syndrome in Commercially-insured and Medicaid Patients: Differences in Patient and Maternal Characteristics and Outpatient Treatment Patterns | Wallace L, Harding B, Matsuno RK
| Thursday, May 1, 9:30 AM 11:00 AM |
About Purdue Pharma L.P.
Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.
Contact: | |
James Heins | Jennifer Soares |
Senior Director, Public Affairs | Senior Manager, Corporate Affairs & Communications |
office: 203-588-8069 | office: 203-588-7623 |
mobile: 203-856-2121 | mobile: 203-609-1746 |
Email: james.heins@pharma.com | email: jennifer.soares@pharma.com |
SOURCE Purdue Pharma L.P.
Help employers find you! Check out all the jobs and post your resume.
